Eli Lilly and Company (NYSE:LLY) Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,250 shares of the company’s stock after selling 531 shares during the period. Eli Lilly and Company comprises approximately 0.9% of CHICAGO TRUST Co NA’s portfolio, making the stock its 22nd largest position. CHICAGO TRUST Co NA’s holdings in Eli Lilly and Company were worth $4,825,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of LLY. Lyell Wealth Management LP grew its stake in shares of Eli Lilly and Company by 0.7% in the second quarter. Lyell Wealth Management LP now owns 2,481 shares of the company’s stock worth $2,246,000 after acquiring an additional 18 shares in the last quarter. Vista Capital Partners Inc. lifted its position in shares of Eli Lilly and Company by 5.7% during the 2nd quarter. Vista Capital Partners Inc. now owns 1,069 shares of the company’s stock worth $968,000 after purchasing an additional 58 shares during the last quarter. Seven Mile Advisory lifted its position in shares of Eli Lilly and Company by 4.0% during the 2nd quarter. Seven Mile Advisory now owns 1,136 shares of the company’s stock worth $1,028,000 after purchasing an additional 44 shares during the last quarter. Diversify Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $4,067,000. Finally, Wilkins Investment Counsel Inc. lifted its position in shares of Eli Lilly and Company by 8.4% during the 2nd quarter. Wilkins Investment Counsel Inc. now owns 3,104 shares of the company’s stock worth $2,810,000 after purchasing an additional 240 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on LLY. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Bank of America reissued a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Wolfe Research started coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Finally, Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $7.67 on Monday, hitting $792.23. The company’s stock had a trading volume of 1,211,595 shares, compared to its average volume of 2,824,737. Eli Lilly and Company has a 12-month low of $612.70 and a 12-month high of $972.53. The company has a market capitalization of $752.08 billion, a price-to-earnings ratio of 85.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a 50 day moving average of $786.08 and a 200-day moving average of $859.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. Eli Lilly and Company’s dividend payout ratio is presently 64.86%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.